Maxigen Biotech Inc
TWSE:1783
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| TW |
|
Maxigen Biotech Inc
TWSE:1783
|
4.1B TWD |
Loading...
|
|
| FR |
|
L'Oreal SA
PAR:OR
|
212.9B EUR |
Loading...
|
|
| UK |
|
Unilever PLC
LSE:ULVR
|
112.9B GBP |
Loading...
|
|
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.6T INR |
Loading...
|
|
| UK |
|
HALEON PLC
LSE:HLN
|
35.7B GBP |
Loading...
|
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
42.9B USD |
Loading...
|
|
| DE |
|
Beiersdorf AG
XETRA:BEI
|
22.7B EUR |
Loading...
|
|
| JP |
|
Kao Corp
TSE:4452
|
2.9T JPY |
Loading...
|
|
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.2T INR |
Loading...
|
|
| IN |
|
Dabur India Ltd
NSE:DABUR
|
891.5B INR |
Loading...
|
|
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD |
Loading...
|
Market Distribution
| Min | -22 082.4% |
| 30th Percentile | 1% |
| Median | 5.3% |
| 70th Percentile | 11.1% |
| Max | 1 580% |
Other Profitability Ratios
Maxigen Biotech Inc
Glance View
Maxigen Biotech, Inc. engages in the research, development, manufacturing, and sales of biomedical materials and beauty care products. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2011-05-18. The firm operates through two main segments. The Consumer Products segment is mainly engaged in the wholesales of cleansing products, facial care products, medical beauty products and others. The Biomedical Products is mainly involved in the manufacture and sales of Formagraft collagen and ceramic composite material products, Foramic ceramic bone feed materials, Artiaid hyaluronic acid joint injection products, ViscAid ophthalmology viscoelastic agents, as well as SurgiAid wound collagen materials and others.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Maxigen Biotech Inc is 29.5%, which is above its 3-year median of 27.3%.
Over the last 3 years, Maxigen Biotech Inc’s Net Margin has increased from 18.9% to 29.5%. During this period, it reached a low of 18.9% on Aug 30, 2022 and a high of 30% on Sep 30, 2023.
